Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.
about
VEGF-Trap: a VEGF blocker with potent antitumor effects.Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer.Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth.Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells.Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft modelEvading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsMechanisms of vascularization in murine models of primary and metastatic tumor growthContrast-enhanced ultrasonography in peripheral lung consolidations: What's its actual role?Contrast enhanced ultrasonography (CEUS) in peripheral lung lesions: A study of 60 cases.Tumour vascularization: sprouting angiogenesis and beyondResistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesisThe Way that PEGyl-DSPC Liposomal Doxorubicin Particles Penetrate into Solid Tumor Tissue.A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity.Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancerAngiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration.Blood vessels and cancer much more than just angiogenesis.Intra-tumoural microvessel density in human solid tumours.Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cellsClinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells.Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas.The clinical potential of antiangiogenic fragments of extracellular matrix proteinsRedirecting Transport of Nanoparticle Albumin-Bound Paclitaxel to Macrophages Enhances Therapeutic Efficacy against Liver MetastasesIs nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructionsMicrovascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progressionProspective study of intratumoral microvessel density, p53 expression and survival in colorectal cancerPrognostic value of nonangiogenic and angiogenic growth patterns in non-small-cell lung cancer.Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hopeEnhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesionsVessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular CarcinomaDifferential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.Controlling escape from angiogenesis inhibitors.Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas.
P2860
Q24535043-4A313096-14EC-4D70-8F47-259CB298882DQ24797550-E7620175-BAAE-4EB2-9754-74027C9A7E6AQ24800330-9E302B41-5B06-4243-80D6-9EB7CC5A7206Q24800983-53F0C241-979D-45E7-B622-31243289C6BDQ24803460-68EADBB6-CBA5-4599-B25B-1A98544744D3Q26773795-AFD97B73-461B-43FB-BEBA-78D8060BC15BQ28077790-BBCCC74A-B206-4F0F-83A2-4AE22468E379Q30447908-B183DDAB-DE72-4E7E-855A-E6AF1E539CB2Q30458376-BA3A7E28-C9A2-48B2-ADCA-B2E936401756Q33556162-3B72BD64-C5EF-4993-8AE9-FB5962E1E7A4Q33730122-7FB5703E-2B84-4384-934A-3090A14EBD34Q33770680-57305451-B555-4D9D-9533-E7F970979709Q33959044-5087D518-2500-4707-8E65-CC9CF0ECA0C0Q34013560-368F19AA-8ECD-431A-9D69-FE1552BA09ADQ34099015-FC6CFD04-8125-43B4-B607-3A1AC217DAEEQ34128953-CA0906A2-D8FD-46E4-ACC9-0D7CA7EFCFACQ34130424-20F67DD4-431B-42A1-A00A-15E05A6BEF26Q34538155-1EFE803F-1529-4ECE-BD9D-97D612731674Q34708258-AF336007-0227-4049-A633-D34F7F1A0B68Q34972161-800CB02F-A23E-4999-BD42-7B1B9E7E9D1DQ35570450-638ADFF0-E135-4758-B685-99ABE12D4387Q35633657-06BA248C-0B39-41C8-9D49-1C41057E50D8Q35779978-AAE7FA61-2C61-4405-B832-6BD5AC89741FQ35845212-5C2528CB-3371-49EC-B1C5-FC5CCF347914Q36290509-8CFB969D-DB75-4E2A-93D6-3537DCD15C04Q36471409-E8DA30C8-BEED-4676-8E7A-BDDAD655BB69Q36614128-4743A2C0-536F-4098-ABA3-7AA86D85B245Q36615803-EDF9D3B5-C596-479B-85FE-98380EEE2AF4Q36617353-89414E4D-A7EB-47D3-901D-9BF3DC91F07DQ36695762-D812679A-6F0A-4391-847F-149A1DC3EB4DQ36884230-6D1C410A-A562-472B-BCCB-20F09155D9F7Q37033738-77D3A109-3EA9-4F9C-A9B3-FCDB08D38AE9Q37236229-8809562B-BC18-4829-B7F6-E24F47916652Q37245796-1AE66B09-0CB1-4BB3-A744-BBC79BF0F5C5Q37284263-DC722FFA-66FE-4ED7-9E33-A8184741855CQ37389411-BD75DF69-0247-464E-B75E-A2DEB2F7A34AQ37595980-2FB6248D-572E-48AD-892A-149F0BCF7579Q37672654-2412734A-44CD-460B-94BF-7DE8E1FCE1BBQ37846342-2A758BCE-4119-4DD1-A3E7-21B64ACB1E3EQ38281714-2E84EF3A-B065-4CFB-BD3D-2C4F7E7C5279
P2860
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Non-small-cell lung carcinoma ...... evidence of neo-angiogenesis.
@ast
Non-small-cell lung carcinoma ...... evidence of neo-angiogenesis.
@en
type
label
Non-small-cell lung carcinoma ...... evidence of neo-angiogenesis.
@ast
Non-small-cell lung carcinoma ...... evidence of neo-angiogenesis.
@en
prefLabel
Non-small-cell lung carcinoma ...... evidence of neo-angiogenesis.
@ast
Non-small-cell lung carcinoma ...... evidence of neo-angiogenesis.
@en
P2093
P2860
P1476
Non-small-cell lung carcinoma ...... l evidence of neo-angiogenesis
@en
P2093
Andreola S
Gasparini G
Pastorino U
Pezzella F
P2860
P304
P407
P577
1997-11-01T00:00:00Z